S-Ketamine
Chronic Rhinosinusitis
The Second People's Hospital of Huai'anPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Chronic Rhinosinusitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cipralex University of Washington | Phase 4 | BB |
Omalizumab University of California, San Francisco | Phase 4 | BB |
METHOXIFLURANE St. Paul's Hospital, Canada | Phase 1/2 | CCC |
LAVENDER OIL Cedars-Sinai Medical Center | N/A | D |
Ivacaftor University of California, Los Angeles | D |
View all 9 →
Same molecule, other indications
S-Ketamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →